S-1/A: Applied DNA Sciences Seeks to Resell 11.3 Million Shares Underlying Common Warrants

Applied DNA Sciences has filed an amendment to its S-1 registration statement to allow selling stockholders to resell up to 11,288,122 shares of common stock underlying common warrants.

Summary

• Applied DNA Sciences has filed an Amendment No. 1 to Form S-1 registration statement with the SEC.
• The registration statement relates to the resale of up to 11,288,122 shares of common stock by selling stockholders, which may be acquired upon the exercise of outstanding common warrants.
• The common warrants were issued in a private placement concurrent with a registered direct offering of common stock and pre-funded warrants, which closed on February 2, 2024.
• Each common warrant has an exercise price of $0.609 per share and will become exercisable upon shareholder approval.
• The common warrants will expire five years after shareholder approval.
• The company will not receive any proceeds from the resale of common stock by the selling stockholders, but will receive proceeds from any cash exercise of the common warrants.
• The company intends to use the net proceeds from any cash exercise of the common warrants for working capital and general corporate purposes.
• On March 14, 2024, the last reported sale price of Applied DNA Sciences' common stock was $0.37 per share.
• The company is a smaller reporting company and has elected to comply with certain reduced reporting requirements.
• Investing in the company's securities involves a high degree of risk.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential of the Linea DNA and IVT platforms, the company faces significant challenges including limited revenue, doubt about its ability to continue as a going concern, and non-compliance with Nasdaq's minimum bid requirements. The need for additional financing and the competitive landscape also contribute to a cautious outlook.

Positives

• The company's Linea DNA platform offers several advantages over existing cell-based plasmid DNA manufacturing platforms, including speed, scalability, purity, simplicity, and flexibility.
• The company's Linea IVT platform enables customers to make better mRNA, faster, and potentially increases the company's mRNA-related total addressable market (TAM) by approximately 3x.
• The company plans to offer several quality grades of Linea DNA, each of which will have different permitted uses.
• The company anticipates that the proceeds from the Offering should be sufficient to support the costs of the critical starting materials fit-for-purpose manufacturing facility.
• The company's business plan is to leverage growing consumer and governmental awareness for product traceability catalyzed by the UFLPA to expand existing partnerships and seek new partnerships for its DNA Tagging and Security Products and Services with a focus on cotton.

Negatives

• The company has produced limited revenue, making it difficult to evaluate future prospects.
• There is substantial doubt relating to the company's ability to continue as a going concern.
• The company may require additional financing, which may dilute the ownership held by stockholders.
• The company's operating results could be adversely affected by a reduction in business with significant customers.
• The company's current emphasis on Therapeutic DNA Production Services may reduce its ability to maintain and expand existing MDX Testing Services and DNA Tagging and Security Products and Services businesses.
• The company's safeCircle COVID-19 testing service could become obsolete or its utility could be significantly diminished, including in light of significantly decreasing demand for COVID-19 testing services.
• The company has received written notice from Nasdaq that it is not in compliance with Nasdaq's minimum bid requirements, and if it is unable to regain compliance, it could be delisted from Nasdaq.

Risks

• The company's opportunities to work with customers to develop pharmaceuticals and biologics will require substantial additional funding.
• The company may not successfully implement its business strategies, including achieving its growth objectives.
• The company may encounter difficulties in managing its growth, which could impair its profitability.
• If the company is unable to expand its DNA manufacturing capacity, it could lose revenue and its business could suffer.
• Rapidly changing technology and extensive competition in synthetic biology could make the services or products the company is developing obsolete or non-competitive.
• Pharmaceutical and biologic products are highly complex, and if the company or its collaborators and customers are unable to provide quality and timely offerings, the business could suffer.
• The company will need to develop and maintain manufacturing facilities that meet GMP standards.
• Pharmaceutical and biologic-related revenue will be dependent on collaborators' and customers' demand for manufacturing services.
• The markets for drug and biologic candidates and synthetic DNA are very competitive.
• The markets for the company's supply chain security and product authentication solutions are very competitive.
• The company competes with larger life science, pharmaceutical, and biotechnology companies.
• The company's intellectual property rights are valuable, and any inability to protect them could reduce the value of its products, services, and brand.
• Pharmaceutical and biologic-related revenue is generally dependent on regulatory approval, oversight, and compliance.
• If the FDA were to begin to enforce regulation of laboratory-developed tests, the company could incur substantial costs and delays.
• If the company fails to comply with laboratory licensing requirements, it could lose the ability to offer clinical testing services.
• If the company fails to comply with healthcare laws, it could face substantial penalties.
• If the company is unable to continue to retain the services of Dr. Hayward, it may not be able to continue its operations.
• The company may have conflicts of interest with its affiliates and related parties.
• There are a large number of shares of common stock underlying outstanding options and warrants, and the sale of these shares may depress the market price of the common stock and cause dilution.
• The exercisability of the common warrants is contingent upon the company obtaining shareholder approval, and if the company does not obtain such approval, the common warrants may never become exercisable.

Future Outlook

The company plans to capitalize on the rapid growth of mRNA therapies and expand its contract development and manufacturing operation (CDMO) for the manufacture of synthetic DNA for use in the production of nucleic acid-based therapies. The company also plans to leverage its Therapeutic DNA Production Services to develop Linea DNA-based therapeutic or prophylactic vaccines for high-value veterinary health indications.

Industry Context

The document highlights the growing market for mRNA therapies and the increasing demand for DNA in the production of nucleic acid-based therapeutics. The company aims to position itself as a key player in this market by offering its Linea DNA and Linea IVT platforms. The document also mentions the Uyghur Forced Labor Prevention Act (UFLPA) and the growing consumer and governmental awareness for product traceability, which the company aims to leverage to expand its DNA Tagging and Security Products and Services.

Comparison to Industry Standards

• The document mentions that as of the fourth quarter of calendar year 2023, there were 3,951 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process.
• The document also mentions that as of the 4th quarter of calendar 2023, there were almost 425 mRNA therapies under development, with the large majority of these therapies (67%) in the preclinical stage.
• The document compares the Linea DNA platform to plasmid-based DNA manufacturing technologies, highlighting the advantages of the Linea DNA platform in terms of speed, scalability, purity, simplicity, and flexibility.
• The document compares the Linea IVT platform to conventional mRNA production, highlighting the advantages of the Linea IVT platform in terms of the prevention or reduction of double stranded RNA (dsRNA) contamination, delivery of IVT templates, and reduced mRNA manufacturing complexities.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised and new shares are issued.
• Employees' stock options and equity-based compensation may be affected by the stock price and potential dilution.
• Customers in the pharmaceutical and biotechnology industries may benefit from the company's Linea DNA and IVT platforms.
• The company's suppliers and partners may be affected by the company's financial performance and ability to execute its business strategy.
• Creditors may be concerned about the company's ability to repay its debts if it does not achieve its growth objectives.

Next Steps

• The company intends to use the net proceeds from any cash exercise of the common warrants for working capital and general corporate purposes.
• The company intends to actively monitor the bid price for its Common Stock and will consider available options, including effecting a reverse stock split, to regain compliance with the Minimum Bid Price Requirement.
• The company plans to offer several quality grades of Linea DNA, each of which will have different permitted uses.
• The company plans to offer Linea DNA materials manufactured under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, with availability expected during the first half of calendar year 2025, dependent upon the availability of future funding.
• The company plans to leverage its Therapeutic DNA Production Services and deep knowledge of PCR to develop and monetize, themselves or with strategic partners, one or more Linea DNA-based therapeutic or prophylactic vaccines for high-value veterinary health indications.

Key Dates

Keywords

common stock, warrants, resale, registration statement, Applied DNA Sciences, Therapeutic DNA Production Services, Linea DNA, mRNA, MDx Testing Services, DNA Tagging, Security Products, biotechnology